Cost of neutropenic complications of chemotherapy

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 454-460

  Weycker, D ^a   Malin, J ^b   Edelsberg, J ^a   Glass, A ^c   Gokhale, M ^a   Oster, G ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b AMGEN INC   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Costs and cost analysis; Fever; Infection; Neoplasms; Neutropenia

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT DURATION; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; COHORT STUDIES; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 40149086980     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm525     Document Type: Article

References (18)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
2. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-1332.
3. Pizzo PA. Evaluation of fever in the patient with cancer. Eur J Cancer Clin Oncol 1989; 25: S9-S16.
4. Ozer H, Armitage JO, Bennett CL et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558-3585.
5. Lyman GH, Kuderer N, Greene J, Baducci L. The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer 1998; 34: 1857-1864.
6. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103: 1916-1924.
7. Kuderer NM, Dale DC, Crawford J, Cosler LE et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-2266.
8. Health Insurance Portability and Accountability Act of 1996, 42 USC 1§320-d2.
9. Public Welfare - Protection of Human Subjects; 45CFR 46 4§6.101.
10. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
11. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516-524.
12. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993; 46 (10): 1075-1079.
13. Weycker D, Hackett J, Edelsberg JS, Oster G et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006; 40: 402-407.
14. Smith TJ, Khatcheressian J, Lyman GH, Ozer H et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
15. Cosler LE, Sivasubramaniam V, Agboola O, Crawford J et al. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value in Health 2005; 8: 47-52.
16. Weycker D, Malin J, Glass A, Oster G. Economic Burden of Chemotherapy-Related Febrile Neutropenia Treated in Inpatient and Outpatient Settings. Presented at the American Society of Health-System Pharmacists Summer Meeting, Orlando, Florida, 25-28 June, 2206.
17. Livingston RB. Dose intensity and high dose therapy; two different concepts. Cancer 1994; 74: 1177-1183.
18. Petros WP, Peters WP. Hematopoietic colony-stimulating factors and dose intensity. Semin Oncol 1993; 20: 94-99.